Prospective genotype-guided drug selection and dosing in alcohol withdrawal syndrome complicated by seizures: a randomized clinical trial
Gene–drug pair / mechanism
Benzodiazepine and anticonvulsant selection and dosing guided by genotyping of CYP2D6, CYP2C19, CYP3A4, CYP3A5 and ABCB1
Summary
This single-centre randomised trial allocated 100 inpatients with alcohol withdrawal complicated by seizures to genotype-guided prescribing or control. All were genotyped on admission (CYP2D6*4, CYP2C19*2, CYP2C19*17, CYP3A4*1B, CYP3A5*3 and ABCB1 3435C>T); only the intervention group received recommendations on benzodiazepine and anticonvulsant selection and starting dose. The 72-hour CIWA-Ar area under the curve was lower with the guided strategy (774.3 vs 903.6; difference -129.3; 95% CI -204.0 to -54.6; p<0.001), with less excessive sedation (1/50 vs 9/50) and a lower benzodiazepine load (25.0 vs 27.5 mg diazepam equivalents). Confirmed stabilisation by 48 hours (31/50 vs 20/50) was no longer significant after multiplicity correction (adjusted p = 0.051).
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The most telling result is excessive sedation (1/50 vs 9/50), since the secondary stabilisation endpoint does not survive multiplicity correction. The intervention changes both anticonvulsant selection and doses, and drug concentrations were not measured: the trial supports a strategy, not a genotype-to-dose rule, as the authors state. Single-centre with 100 patients, it calls for multicentre replication.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime